High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin

Digestive Diseases and Sciences

Volumn 50, Issue 4, 2005, Pages 634-639

  Rodríguez Torres, Maribel ^a,c,e   Salgado Mercado, Rosa ^a   Ríos Bedoya, Carlos F ^c   Aponte Rivera, Edgardo ^a   Marxuach Cuétara, Acisclo M ^a   Rodríguez Orengo, José F ^b   Fernández Carbia, Alberto ^d  

^a Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^d University Pathologists   (Puerto Rico)

^e Fundacion de Investigacion de Diego   (Puerto Rico)

Author keywords

Esomeprazole; First line therapy; Helicobacter pylori; Penicillin free; Second line therapy

Indexed keywords

ESOMEPRAZOLE; FLUCONAZOLE; METRONIDAZOLE; NYSTATIN; PENICILLIN G; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BACTERIAL INFECTION; BIOPSY; CLINICAL ARTICLE; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; EROSIVE GASTRITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HELICOBACTER PYLORI; HUMAN; INFECTION; MALAISE; MALE; NAUSEA; PEPTIC ULCER; PRIORITY JOURNAL; SYSTEMIC DISEASE; THRUSH; TREATMENT FAILURE; ULCER HEALING;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; TETRACYCLINE; TREATMENT OUTCOME;

EID: 17644374149     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2549-1     Document Type: Article

References (27)

1. Go MF: Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 16(Suppl 1):3-15, 2002
2. Blaser MJ: Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 179:1523-1530, 1999
3. Rauws EAJ, Tytgat GNY: Cure of duodenal ulcer disease associated with eradication of Helicobacter Pylori. Lancet 2:1233-1235, 1990
4. Megraud F, Brassens-Rabbe MP, Denis F: Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 27:1870-1873, 1989
5. Zarrilli R, Ricci V, Romano M: Molecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage. Cell Microbiol 1:93-99, 1999
6. Peek RM Jr, Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev Cancer 2:28-37, 2002
7. NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69, 1994
8. Malfertheiner P, Megraud F, O Morain C: Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Concensus Report. Aliment Pharmacol Ther 16:167-180, 2000
9. Gisbert JP, Pajares JM, Racz I: The year in Helicobacter pylori therapy 2001. Curr Opin Gastroenterol 17(Suppl 1):S47-S54, 2001
10. Megraud F: Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 115:1278-1272, 1998
11. Graham DY: Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115:1272-1277, 1998
12. Huang J, Hunt RH: The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycicn and amoxicillin or metronidazole. Aliment Pharmacol Ther 13:719-729, 1999
13. Gerrits MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbroucke-Grauls CM, Kusters JG: Alterations in penicillin-binding protein IA confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 46:2229-2233, 2002
14. Kwon DH, Kim JJ, Lee M, et al.: Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 44:3203-3205, 2000
15. Iovene MR, Romano M, Pilloni AO, et al.: Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy. 45:8-14, 1999
16. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vanderbroucke-Grauls CM: Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in the Netherlands. J Antimicrob Chemother 43:511-415, 1999
17. Laine L, Fennerty MB, Suchower L, et al.: H. pylori antibiotic resistance, eradication and emergent resistance in U.S. double-blind trials of esomeprazole, clarithromycin, and amoxicillin. Gastroenterology 118(Suppl 2):A498, 2000
18. Vergara M, Vallve M, Gisbert JP, Calvet X: Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 18(6):647-654, 2003
19. Laine L: Review article: esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 16(Suppl 4): 115-118, 2002
20. Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, Rudzinski J, Bartuzi Z, Hasselgren G, Larko A, Wrangstadh M: One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 13(12):1457-1465, 2001
21. Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC, Labenz J, De Argila CM, Lind T, Treichel HC, Stubberod A, Cockeram A, Hasselgren G, Gothe L, Wrangstadh M, Sinclair P: One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 14(12):1605-1611, 2000
22. Veldhuyzen Van Zanten S, Machado S, Lee J: One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 17(11):1381-1387, 2003
23. Miehlke S, Schneider-Brachert W, Bastlein E, Ebert S, Kirsch C, Haferland C, Buchner M, Neumeyer M, Vieth M, Stolte M, Lehn N, Bayerdorffer E: Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. Aliment Pharmacol Ther 18(8):799-804, 2003
24. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG: Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 95(12):3393-3398, 2000
25. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J: Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 17(1):119-123, 2003
26. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Amim U, Kahl S, Stolte M, Borsch G, Labenz J, Malfertheiner P: High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 16(2):315-324, 2002
27. Baena Diez JM, Lopez Mompo C, Rams Rams F, Garcia Lareo M, Rosario Hernandez Ibanez M, Teruel Gila J: Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxicillin. Med Clin 115(16):617-619, 2000